Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
A FORGIVENESS-BASED APPROACH: AN ANALYSIS OF FORGIVENESS AND ITS USES IN THE BASQUE CONFLICT (FORGIVEBASQ)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Global Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Social Sciences and Humanities
Countries involved: Spain,United States
Call: Individual Fellowships (H2020-MSCA-IF-2019, 2019)
Start date: 2021-02-01
End date: 2024-01-31
Duration (months): 24.0
Total project cost (EUR): 175099.2
EU funding (EUR): 175099.2
Participants: 2
Project status: SIGNED

From the second half of the twentieth century, forgiveness has come to occupy an important place in political transition processes, both in the passage from dictatorship to democracy and at the end of violent internal political conflicts. The implications of forgiveness are not limited to moral or religious issues, but also involve social, political and legal aspects that further complicate the widely disparate interpretations of its conditions (acknowledgement of fault, repentance, etc.) and purposes (reconciliation, social cohesion, justice, etc.). FORGIVEBASQ aims to study the uses of forgiveness in the Basque conflict and its role in the current peace process. Firstly, I will develop a theoretical framework on forgiveness by adopting a philosophical approach that incorporates a transversal moral, political and social perspective and helps to illustrate its complex transformations and diverse practices. This transdisciplinary theoretical framework will be articulated around three axes: history, areas and conditions/purposes of forgiveness. Secondly, a diachronic study of forgiveness in the Basque context will be carried out by means of a documentary analysis. This will serve to identify and explain how forgiveness has been present in the Basque conflict, what role it plays in the peace process, how it has evolved and been transformed, and the key points at which forgiveness emerged in the political and social debate. Previously developed analytical tools will be employed in this endeavor. Training activities and academic dissemination measures will be complemented by transfer activities that include meetings and public activities with Basque institutions and social organizations. This will go hand-in-hand with the development of educational resources that will use the project findings to achieve a significant social impact.

Keywords: forgiveness,basque conflict
Top down regulation of motivated behaviors by lateral septal integration of cortico-hippocampal inputs (MotivatedBehaviors)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Starting grants
Action type: ERC actions
Panel: Neuroscience and Disorders of the Nervous System
Panel description: Nervous system development, homeostasis and ageing, nervous system function and dysfunction, systems neuroscience and modelling, biological basis of cognitive processes and of behaviour, neurological and mental disorders
Countries involved: Spain
Call: ERC STARTING GRANTS (ERC-2020-STG, 2020)
Start date: 2021-01-01
End date: 2025-12-31
Duration (months): 60.0
Total project cost (EUR): 1735375.0
EU funding (EUR): 1735375.0
Participants: 1
Project status: SIGNED

How does cognition regulate innate “low-level” behaviors? While the cognitive functions of the prefrontal cortex (PFC) and hippocampus have been extensively studied, we know much less about their ability to regulate the activity of the various hypothalamic nuclei controlling motivated behaviors (sociability, aggression, mating, feeding). Living in society nonetheless requires that our past experiences and decision-making exert some degree of control over our “basic” behaviors. The lateral septum (LS) -receiving inputs from PFC and hippocampus and projecting primarily to the hypothalamus- is ideally positioned to integrate cognitive information and, in turn, regulate motivated behaviors. Thus I characterized in mice a novel circuit by which hippocampal CA2 projections to LS result in disinhibition of an aggression-promoting nucleus of the hypothalamus. I also showed that vasopressin enhances aggression through presynaptic facilitation of CA2 inputs to LS. Using this study as a blueprint, I will determine the logic by which LS integrates and compute cognitive inputs to regulate other motivated behaviors. As motivated behaviors depend on internal states, I will also explore how modulatory inputs (vasopressin, dopamine, serotonin) from subcortical brain regions to LS can regulate its function. Finally, since hippocampus, PFC and LS are implicated in several psychiatric disorders associated with altered social behaviors (schizophrenia, autism or bipolar disorder), insights into how these regions regulate motivated behaviors are critical for understanding both basic neural mechanisms as well as how disease processes lead to altered social interactions. This project therefore also aims to unravel potential changes occurring in disorders associated with social behavioral deficits with the ultimate goal of providing new therapeutic targets for disease treatment. Thus my study may suggest new approaches to treat abnormal social cognition associated with psychiatric disorders.

Keywords: motivated behaviors,vasopressin,social aggression
Glycomic and Genomic Repercussion of Nebulisable Gal-3 Inhibitory Medical Device Treatment in Pulmonary Fibrosis (Pulmonary Fibrosis)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Global Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Information Science and Engineering
Countries involved: Ireland,United States
Call: Individual Fellowships (H2020-MSCA-IF-2020, 2020)
Start date: 2022-09-01
End date: 2025-08-31
Duration (months): 36.0
Total project cost (EUR): 257561.28
EU funding (EUR): 257561.28
Participants: 2
Project status: SIGNED

Idiopathic Pulmonary Fibrosis (IPF) accounts for a progressive pathology with extremely high mortality and no cure available. There is a need to study pathology mechanisms for efficient treatments development. Galectin-3 (Gal-3) has shown promising effects in slowing down IPF. In this project, I will optimise nebulisation of a novel Gal-3 inhibitory drug (TD139) hydrogel treatment in bleomycin-induced PF mice model, perform an exhaustive genomic analysis to assess single-cell RNA trajectories during pathology recovery, and analyse tissue glycosylation patters for disease correlation. All this will allow for information on diseases and healing mechanisms to development efficient biomaterials treatments and contribute to the 3rd Sustainable Development Goal of the United Nations “Good Health and Well-Being” for all. I will perform nebulisation studies during secondment in specialised aerosol drug delivery industry (Aerogen®/John Power) (Ireland), in vivo model and exhaustive genomic analysis during outgoing phase in IPF genomic expert lab (Prof Kaminski) at PCCSM, Yale School of Medicine (US), and thorough lectin microarray analysis during incoming phase in glycolbiologist and biomaterials expert lab (Prof Pandit) at CÚRAM, NUI Galway (Ireland). The high expertise of the supervisors, my expertise in biomaterials, the highly qualified and prestigious hosts infrastructures and the intersectoral, international and interdisciplinary aspects of the action will promote my skills for eligibility for the EU Research Council Starting Grant. This will allow me to stablish a Biomaterial Therapies Critical Mass for Respiratory Diseases (RD) in EU and comply with the EU Respiratory Society objective to promote scientific excellence to alleviate suffering of RD. In addition, I will work in a detailed career development plan to promote translation, research integrity, inclusion of minorities, audience engagement and gender dimension for a more impactful and representative research.

Keywords: pulmonary fibrosis,nebuliser,td139,galectin 3,hyaluronic acid,genomics,glycomics
Magnetic Control of Polymorphism in Pharmaceutical Compounds (MagnaPharm)

Framework: Horizon 2020 — Excellent Science
Programme: Future and Emerging Technologies (FET)
Theme: EIC Pathfinder
Destination: Novel ideas for radically new technologies
Action type: Research and Innovation actions
Countries involved: Ireland,Netherlands,United Kingdom,United Kingdom
Call: FET-Open research and innovation actions (H2020-FETOPEN-1-2016-2017, 2016)
Start date: 2017-01-01
End date: 2021-06-30
Duration (months): 54.0
Total project cost (EUR): 2886323.75
EU funding (EUR): 2886323.75
Participants: 4
Project status: CLOSED

This H2020-FETOPEN-2016-2017 proposal initiates a major international effort to direct polymorphism in pharmaceutical compounds through crystallizing in high magnetic fields. The ability to direct polymorphism would have a transformative effect on almost all pharmaceutical compounds, and hence on society. It is proposed that MagnaPharm will drive forward innovation in pharmaceuticals by exploiting our new discovery that the polymorph and properties of carbamazepine, indomethacin and coronene can be controlled through the application of magnetic fields. We will apply our method to a range of pharmaceutical compounds, as guided by our project partner AstraZeneca, one of the largest pharmaceutical companies in the world. We will initially target 12 of the most high-profile, high-worth generic drugs with the aim of controllably synthesizing the desired polymorph of each (the lowest-energy polymorph and/or most processable form with desired properties). We aim for this goal via an international multidisciplinary approach centred around our discovery, underpinned by the development of a profound theoretical understanding of the effects of magnetic fields on organic crystal growth, that will direct the synthetic effort, all drawing on results from cutting edge spectroscopic and crystallographic characterisations. With the 12 representative generic drug molecules targeted in the initial stages of MagnaPharm responsible for €18 billion of sales per year worldwide, and the development of many new pharmaceuticals being hampered by solid form issues, control over the production of the most pharmaceutically desired crystal is a truly paradigm-shifting prospect.

Keywords: organic crystals,polymorphism,crystal simulation,pharmaceuticals
TRANS-NATIONAL COOPERATION AMONG ICT NCPS - IDEALIST2020 (Idealist2020)

Framework: Horizon 2020 — Industrial Leadership
Programme: Information and Communication Technologies
Action type: Coordination and support actions
Countries involved: Austria,Armenia,Iceland,Spain,Albania,Ukraine,Italy,Israel,Cyprus,Switzerland,North Macedonia,Belgium,Bosnia and Herzegovina,Bulgaria,Norway,Croatia,Hungary,Slovakia,Greece,Poland,Romania,Moldova, Republic of,Georgia,Latvia,France,France,Czechia,Luxembourg,Portugal,United Kingdom
Call: Fostering transnational cooperation between National Contact Points (NCP) in the area of ICT: follow-up project (H2020-IBA-ICT-NCP-2018, 2018)
Start date: 2019-01-01
End date: 2021-06-30
Duration (months): 30.0
Total project cost (EUR): 1633874.99
EU funding (EUR): 1499999.99
Participants: 31
Project status: CLOSED

This is the continuation project of the Ideal-ist network - the network for National Contact Points (NCP) of Information and Communication Technologies (ICT). The objective of Ideal-ist is to foster trans-national cooperation among National Contact Points (NCP) in the area of Leadership in Enabling and Industrial Technologies (LEIT) Information and Communication Technologies (ICT) under Horizon2020. The project will deliver trans-national services offering tangible benefits to Ideal-ist users; proposers and NCPs, and other projects, by supporting knowledge sharing, networking and proposal development activities. This cooperation will also include collaboration and networking with similar networks in parallel themes (Security, ENV, Transport, Energy, Health, etc.), especially in the context of joint/coordinated or PPP calls. Ideal-ist will be built upon experience gained over more than 20 years from the preceding projects, starting in FP4, and the cooperation of NCPs in the network and those supporting the network.

Keywords: idealist,idealist2018
Ependymal cell Development: New insight into neurological diseases (EDeN)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Consolidator grants
Action type: ERC actions
Panel: Neuroscience and Disorders of the Nervous System
Panel description: Nervous system development, homeostasis and ageing, nervous system function and dysfunction, systems neuroscience and modelling, biological basis of cognitive processes and of behaviour, neurological and mental disorders
Countries involved: France
Call: ERC Consolidator Grant (ERC-2014-CoG, 2014)
Start date: 2015-12-01
End date: 2021-11-30
Duration (months): 72.0
Total project cost (EUR): 1999484.0
EU funding (EUR): 1999484.0
Participants: 1
Project status: CLOSED

Understanding how billions of neurons are born, migrate and integrate into functional circuits has proved useful in elucidating the pathomechanisms of many neurodevelopmental disorders. Multiciliated ependymal cells have attracted less interest and their development is still enigmatic. However, their strategic location at the interface between brain ventricles and parenchyma and their unique morphology and functions strongly suggest that defects in the generation of these cells may be associated with a variety of severe neurological disorders. Multiciliated ependymal cells are epithelial cells that line all brain ventricles. The coordinated and oriented beating of their cilia is crucial for the flow of cerebrospinal fluid through the ventricles and the migration of new neurons. These cells also provide physical and trophic support that creates a permissive neurogenic environment in the adult. We have shown that elongated bipolar radial glial cells transform into ependymal cells at late embryonic stages through mechanisms that remain largely to be explored. The overall objective of this grant application is to develop a new line of research to understand the cellular and molecular mechanisms involved in ependymal cell development. We will use a multidisciplinary approach involving mouse molecular genetics, biophysical approaches, ex-vivo culture systems and advanced live cell imaging to investigate: i) the mechanisms that direct the transformation of RGC into ependymal cells; ii) the mechanisms of centriole amplification in ependymal cell progenitors; iii) how developing ependymal cells contribute to ventricular morphogenesis and adult neurogenesis. This ambitious project will pave the way for the identification of new therapeutic targets for a variety of neurological disorders.

Keywords: cilia,centrosome,cell specification,cell differentiation,glial cell,genetics,cell biology,live imaging,brain ventricle,ependyma
microRNA assay system based on self-assembled nanoscale DNA origami arrays (miRanDa)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: Switzerland
Call: Individual Fellowships (H2020-MSCA-IF-2019, 2019)
Start date: 2021-06-01
End date: 2023-05-31
Duration (months): 24.0
Total project cost (EUR): 203149.44
EU funding (EUR): 203149.44
Participants: 1
Project status: CLOSED

MicroRNAs (miRNAs) are potential biomarkers for cancer diagnosis, prognosis and treatment monitoring. Specific detection and absolute quantification of miRNAs is of clinical relevance for early cancer detection and monitoring progression. The currently available techniques for miRNA detection based on DNA amplification are limited by lack of absolute quantification, low multiplexing capacity and time consumption. Here, I propose to develop a miRNA assay system based on self-assembled nanoscale DNA origami arrays (miRanDa) for the simultaneous detection of multiple miRNA targets from breast cancer cells and plasma by using DNA-PAINT, state-of-art super resolution technique. The formation of specifically configured finite 2D lattices of self-assembled DNA origami structures based on sticky-end hybridization will further improve the capacity of the detection system beyond the currently available techniques. This assay can be further developed and adapted to the rapid, specific, sensitive and multiple detection of additional nucleic acid species, such as ctDNA, mRNA or lncRNA.

Keywords: microrna,biomarkers,diagnostics,dna nanotechnology,dna origami,dna paint,super resolution microscopy,breast cancer,self assembly
Targeting innate immunity to induce TOLERANCE in transplantation (TOLERANCE)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Advanced grants
Action type: ERC actions
Panel: Prevention, Diagnosis and Treatment of Human Diseases
Panel description: Medical technologies and tools for prevention, diagnosis and treatment of human diseases, therapeutic approaches and interventions, pharmacology, preventative medicine, epidemiology and public health, digital medicine
Countries involved: Netherlands,Netherlands
Call: ERC ADVANCED GRANT (ERC-2020-ADG, 2020)
Start date: 2022-01-01
End date: 2026-12-31
Duration (months): 60.0
Total project cost (EUR): 2500000.0
EU funding (EUR): 1020910.0
Participants: 2
Project status: SIGNED

Transplantation is a life-saving procedure for patients who suffer from end-stage organ failure. While the discovery of potent immunosuppression offers a solution to the previously insurmountable problem of organ rejection, transplant recipients still face substantial problems, including chronic rejection and adverse effects related to the chronic use of immunosuppressive drugs. Therefore, transplantation field’s ‘holy therapeutic grail’ is immunological tolerance induction without the need for chronic immunosuppression. Our recent work has identified innate immune responses, and in particular trained immunity, to play a critical role in transplantation. Based on compelling preliminary data, I hypothesize that trained immunity-induced myelopoiesis and hyperinflammation are proximal causes of T and B cell immunity and therefore are compelling therapeutic targets to induce immunological tolerance and significantly improve allograft survival. We will tackle the central hypothesis from the vantage points of medicine & immunology and biomedical engineering by pursuing two objectives: Objective 1 Medicine & Immunology – To mechanistically decipher innate immune responses and myelopoiesis in kidney transplant patients. Objective 2 Biomedical Engineering – To develop immuno-imaging and nanomedicine approaches that target innate immunity in transplantation. We have developed a comprehensive preclinical development program to evaluate these novel methods in a kidney transplant mouse model. This Program’s successful completion will yield unique nanobiologic immunotherapies and immunoimaging strategies, which can be employed to take control of the innate immune response and promote allograft tolerance in transplantation, but can also be adopted to treat other conditions that are characterized by an exacerbated immune response, including infections, cancer and cardiovascular diseases.

Keywords: nanomedicine,nano immunotherapy,kidney transplantation,molecular imaging,precision medicine
Creating and enhancing TRUSTworthy, responsible and equitable partnerships in international research (TRUST)

Framework: Horizon 2020 — Science with and for Society
Programme: Develop the governance for the advancement of responsible research and innovation by all stakeholders, which is sensitive to society needs and demands and promote an ethics framework for research and innovation
Action type: Coordination and support actions
Countries involved: South Africa,India,Switzerland,Switzerland,Belgium,France,Netherlands,Kenya,United Kingdom
Call: Reducing the risk of exporting non ethical practices to third countries (H2020-GARRI-2014-1, 2014)
Start date: 2015-10-01
End date: 2018-12-31
Duration (months): 39.0
Total project cost (EUR): 2651258.75
EU funding (EUR): 2141173.25
Participants: 13
Project status: CLOSED

The goal of the TRUST Project is to catalyse a global collaborative effort to improve adherence to high ethical standards around the world. Achieving equity in international research is one of the pressing concerns of the 21st century. Many international groups and organisations are working on governance frameworks and standards to guide research activities after progressive globalization. However, their efforts are disparate and lacking a guiding vision. In an interdisciplinary collaboration between multi-level ethics bodies, policy advisors, civil society organisations, funding organisations, industry and academic scholars from a range of disciplines, this project combines long-standing, highly respected efforts to build international governance structures with new exciting network opportunities between Europe, India, Sub-Saharan Africa, China and Russia. TRUST will open up new horizons in improving adherence to high ethical standards in research globally. The project's strategic output are three sets of tools based on participatory engagement covering all continents: (1) a global code of conduct for funders, (2) a fair research contracting on-line tool and (3) a compliance and ethics follow-up tool, which takes limited resources into account.

Keywords: equitable partnerships,compliance,developing countries,research integrity,global justice,international research ethics
AnTBiotic – progressing TB drug candidates to clinical proof of concept (anTBiotic)

Framework: Horizon 2020 — Societal Challenges
Programme: Health, demographic change and wellbeing
Theme: Treating and managing disease
Action type: Research and Innovation actions
Countries involved: South Africa,Germany,Spain,Norway
Call: New therapies for chronic diseases (H2020-SC1-2016-RTD, 2016)
Start date: 2017-01-01
End date: 2022-06-30
Duration (months): 66.0
Total project cost (EUR): 5819416.0
EU funding (EUR): 5819416.0
Participants: 5
Project status: CLOSED

Tuberculosis (TB) today rivals HIV/AIDS as the leading cause of death from infectious diseases. The number of TB patients has never been higher and the growing proportion of drug-resistant TB is threatening control strategies both in the developing and developed world, Eastern Europe being a particularly worrying point in case. The anTBiotic consortium aims to fuel the long-term TB clinical pipeline while immediately offering new options to clinicians when confronted with multidrug-resistant (MDR)-TB. More specifically, the proposed studies aim to: a) Establish the proof of concept of anti-TB efficacy in humans of a pioneering, first-in-class, low-dose GSK oxaborole clinical drug candidate; b) Identify a combination of β-lactam antibiotics suitable for the treatment of MDR TB orally or as a once daily intravenous or intramuscular application and c) Incorporate the best β-lactam combination into an explorative salvage regimen for untreatable patients with extensively drug-resistant TB The anti-TB activity in humans will be established in a two-week EBA clinical studies that combine established (CFU, TTP) and new clinical markers (biomarkers, PET/CT). These datasets will help ascertain anti-TB efficacy in humans and generate confidence on their validity in longer-term drug combination trials. A variety of modelling approaches to predict optimal dosing will be used. Finally, we intend to use at least one of these novel anti-TB entities as part of a pioneering, non-controlled clinical trial in highly drug resistant subjects in Europe and South Africa. This final clinical intervention will hopefully be of immediate benefit to drug-resistant patients in the EU and elsewhere in addition to generating a strong precedent for further adoption worldwide.

Keywords: tuberculosis